依托考昔联合小剂量秋水仙碱治疗急性痛风性关节炎37例疗效观察

Clinical efficacy of etocoxib combined with low dose colchicine in the treatment of acute gouty arthritis in 37 patients

目的观察依托考昔联合小剂量秋水仙碱治疗急性痛风性关节炎(AGA)的临床疗效。方法选取聊城市第二人民医院2019年10月至2021年10月接诊的AGA患者74例,采用随机数字表法分为两组,对照组37例采用依托考昔治疗,观察组37例采用依托考昔联合小剂量秋水仙碱治疗,两组疗程1周。比较两组临床疗效、视觉模拟评分法(VAS)评分、实验室指标、不良反应发生率、生活质量综合评定问卷-74(GQOL-74)评分。结果观察组总有效率为95%(35/37),高于对照组的65%(24/37);治疗1 d、3 d、6 d,观察组VAS评分均低于对照组(t=19.77、15.43、29.01,均P<0.001)。治疗后,观察组血尿酸、C反应蛋白、红细胞沉降率分别为(432.26±31.26)μmol/L、(16.25±1.62)mg/L、(31.26±1.25)mm/h,均低于对照组的(485.26±39.62)μmol/L、(45.26±3.88)mg/L、(46.52±2.82)mm/h,差异均有统计学意义(t=6.39、41.97、30.09,均P<0.001);观察组GQOL-74评分均高于对照组(t=13.41、17.73、16.09、11.77,均P<0.001)。两组不良反应发生率差异无统计学意义(P>0.05)。结论依托考昔联合小剂量秋水仙碱可有效缓解AGA患者疼痛等症状,减轻炎性反应,提高生活质量,且不良反应发生率较低。

Objective To investigate the clinical efficacy of etocoxib combined with low-dose colchicine in the treatment of acute gouty arthritis in 37 patients.Methods A total of 74 patients with acute gouty arthritis who received treatment in The Second People's Hospital of Liaocheng from October 2019 to October 2021 were included in this study.They were randomly assigned to undergo treatment with etocoxib alone(control group,n=37)or etocoxib combined with low-dose colchicine(observation group,n=37).All patients were treated for 1 week.Clinical efficacy,Visual Analogue Scale score,laboratory indicators,incidence of adverse reactions,and Quality of Life Comprehensive Assessment Questionnaire-74 score were compared between the two groups.Results The total response rate in the observation group was significantly higher than that in the control group[95%(35/37)vs.65%(24/37)].At 1,3,and 6 days after treatment,the Visual Analogue Scale score in the observation group was significantly lower than that in the control group(t=19.77,15.43,29.01,all P<0.001).After treatment,blood uric acid,C-reactive protein,and erythrocyte sedimentation rate in the observation group was(432.26±31.26)μmol/L,(16.25±1.62)mg/L,(31.26±1.25)mm/h,respectively,which was significantly lower than(485.26±39.62)μmol/L,(45.26±3.88)mg/L,(46.52±2.82)mm/h in the control group(t=6.39,41.97,30.09,all P<0.001).Quality of Life Comprehensive Assessment Questionnaire-74 score in the observation group was significantly higher than that in the control group(t=13.41,17.73,16.09,11.77,all P<0.001).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Etocoxib combined with low-dose colchicine can effectively reduce pain and inflammatory reactions in patients with acute gouty arthritis and improve quality of life,with a low incidence of adverse reactions.